Arbutus Biopharma Corp
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease. Its development programs target chronic hepatitis B and include imdusiran, a subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor. The company has completed Phase 2a trials combining imdusiran with other agents and is evaluating its potential without an immunotherapeutic. AB-101 is in a Phase 1a/1b clinical trial. Arbutus also licenses its lipid nanoparticle and ligand-conjugate delivery technologies for uses outside hepatitis B, while retaining hepatitis B rights. It earns royalties and milestone payments from technology and product licenses, and has royalty entitlements tied to ONPATTRO sales. Its exclusive license with Genevant supports its LNP technology strategy. Arbutus exits its corporate headquarters in Warminster, Pennsylvania.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ABUS in the last 30 days.
See all $ABUS insider activity →Arbutus Biopharma updated its corporate presentation, reporting $104.6M in cash as of October 31, 2026. The company highlighted its hepatitis B pipeline, including 46% of Phase 2a patients achieving functional cure or discontinuing therapy, and plans for a potential Phase 2b imdusiran trial. AB-101 Phase 1 findings showed full PD-L1 receptor occupancy in 11 of 13 healthy subjects at 40 mg.
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 © 2026 ARBUTUS BIOPHARMA, INC 1 WWW.ARBUTUSBIO.COM © 2026 ARBUTUS BIOPHARMA, INC CORPORATE PRESENTATION Q4 2026 NASDAQ: ABUS © 2026 ARBUTUS BIOPHARMA, INC 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the
Arbutus Biopharma reported Q3 2026 net income of $59.1M, or $0.30 per share, compared to a $7.7M net loss in Q3 2025. The company's cash and marketable securities increased to $337.5M by September 30, 2026, up from $91.5M at the end of 2025. The results reflect a shift from patent-settlement-related cash inflows and ongoing clinical development and patent litigation.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning ABUS (Arbutus Biopharma Corp). Coverage has skewed bullish: 9 bullish, 1 neutral, and 0 bearish.
Recent ABUS coverage spans insider activity, regulation and corporate actions.
Positive Phase 2a results and strong cash position could lift the stock.
The filing provides no new quantitative data; it reiterates existing development plans and cash position.
Earnings beat drives positive sentiment; investors may bid the stock higher.
The removal of the hold removes a regulatory barrier, likely prompting a positive price reaction.
Positive catalyst as regulatory barrier removed.
AlphAI scores every news story that mentions ABUS with an AI model for sentiment and relevance, and aggregates insider trades from Arbutus Biopharma Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Arbutus Biopharma updated its corporate presentation, reporting $104.6M in cash as of October 31, 2026. The company highlighted its hepatitis B pipeline, including 46% of Phase 2a patients achieving functional cure or discontinuing therapy, and plans for a potential Phase 2b imdusiran trial. AB-101 Phase 1 findings showed full PD-L1 receptor occupancy in 11 of 13 healthy subjects at 40 mg.
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 © 2026 ARBUTUS BIOPHARMA, INC 1 WWW.ARBUTUSBIO.COM © 2026 ARBUTUS BIOPHARMA, INC CORPORATE PRESENTATION Q4 2026 NASDAQ: ABUS © 2026 ARBUTUS BIOPHARMA, INC 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the
Arbutus Biopharma reported Q3 2026 net income of $59.1M, or $0.30 per share, compared to a $7.7M net loss in Q3 2025. The company's cash and marketable securities increased to $337.5M by September 30, 2026, up from $91.5M at the end of 2025. The results reflect a shift from patent-settlement-related cash inflows and ongoing clinical development and patent litigation.
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa
Arbutus Biopharma (Nasdaq: ABUS) announced the FDA lifted a clinical hold on its experimental oral hepatitis B drug, AB-101. The company plans to continue development. AB-101 showed promising results in a Phase 1a/1b trial, with evidence of high receptor occupancy and hepatitis B surface antigen decline in some patients.
Nguyen Tuan (Chief Financial Officer) sold (to issuer) 48,081 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($0.24M total) on 2026-10-01.
Androski Lindsay (President and CEO) sold (to issuer) 24,655 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($0.12M total) on 2026-10-01.
Arbutus Biopharma accepted 46M shares at $5.00 per share in its tender offer, which expired on September 29, 2026. The offer aimed to purchase up to $230M of shares. Roivant Sciences tendered 8.97M shares, receiving $44.84M, and now owns 19.5% of outstanding shares.
Roivant Sciences Ltd. sold (to issuer) 8,967,383 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($44.84M total) on 2026-10-01.
Arbutus Biopharma (ABUS) completed a $230M share buyback, retiring 23% of its shares at $5 each. The tender offer was oversubscribed, with 46M shares accepted and 153.3M remaining. Roivant Sciences, holding 19.5%, participated proportionately.
